Pharmaceutical & Life Sciences

Lerner David was among the first law firms to represent pharmaceutical companies in Hatch-Waxman litigation, and from our long-standing relationship with the industry, our pharma and life sciences practice has thrived on our institution knowledge – to the benefit of our clients. Our team melds skilled courtroom and PTAB advocates with crafty IP strategists. We have represented some of the world’s most recognized companies in building patent portfolios and license strategies around New Chemical Entities, formulations, chemical syntheses, and methods of treatment that protect valuable pharmaceutical and biotechnology franchises.  From pre-litigation counseling to Orange Book strategy and FLBs through litigation, post-grant proceedings, as well as appeals involving both ANDAs and 505(b)(2)s, we help our pharma and biotech clients navigate every stage of the Hatch‑Waxman process. We have been involved in many of the blockbuster cases of the past three decades involving such household names as AndroGel®, Ceclor®, Nexium®, Orecea®, OxyContin®, Paxil®, Prevacid®, Taxol®, Zantac®, Zoloft®, and Zofran®.

Lerner David offers its full range of IP services to the pharmaceutical and life sciences industry for companies in all lifecycle stages, from investigational and pre-clinical biotech entities to established generics conglomerates.

REPRESENTATIVE MATTERS